RedHill Biopharma announces development progress for RHB-102

RedHill Biopharma (RDHL) announced development progress for RHB-102 in multiple GI indications, including its development, via the accelerated FDA 505(b)(2) route, as a once-daily oral ondansetron therapy for GLP-1/GIP receptor agonist therapy-associated GI side effects, such as nausea, vomiting and diarrhea, that are estimated to significantly limit growth in the multi-billion-dollar GLP-1 market. RedHill further announced that it is currently pursuing potential U.S. FDA approval of RHB-102 for oncology support, with additional potential for use in post-operative nausea and vomiting. If approved by FDA, RHB-102 could be the first oral 24-hour extended-release ondansetron antiemetic drug for the treatment of CINV/RINV. Expansion of RHB-102’s intellectual property coverage for relevant indications, including GLP-1-associated nausea and vomiting, has also advanced.